More articles from Current Drug Therapy

  • CGRP antagonists for decreasing migraine frequency: New options, long overdue
    Julia Bucklan, DO and Zubair Ahmed, MD
    Cleveland Clinic Journal of Medicine April 2020, 87 (4) 211-218; DOI: https://doi.org/10.3949/ccjm.87a.19048

    CGRP drugs are an exciting frontier, but migraine management is still a combination of lifestyle changes plus treatment.

  • Diabetes management: Beyond hemoglobin A1c
    Vinni Makin, MBBS, MD, FACE and M. Cecilia Lansang, MD, MPH
    Cleveland Clinic Journal of Medicine September 2019, 86 (9) 595-600; DOI: https://doi.org/10.3949/ccjm.86a.18031

    Other factors include cardiovascular benefit, weight control, hypoglycemia risk, and cost.

  • ACE inhibitors and ARBs: Managing potassium and renal function
    Tasnim Momoniat, MBCHB, MRCP (UK), Duha Ilyas, MBBS, MRCP (UK) and Sunil Bhandari, MBCHB, FRCP, PhD, M CLIN EDU, FHEA
    Cleveland Clinic Journal of Medicine September 2019, 86 (9) 601-607; DOI: https://doi.org/10.3949/ccjm.86a.18024

    Concern about hyperkalemia and a decline in renal function has led to underuse of these drugs.

  • Hydroxychloroquine: An old drug with new relevance
    Eugen Alexander Shippey, MD, Vanya D. Wagler, DO, FACP, FACR and Angelique N. Collamer, MD, FACP, FACR
    Cleveland Clinic Journal of Medicine June 2018, 85 (6) 459-467; DOI: https://doi.org/10.3949/ccjm.85a.17034

    This antimalarial drug is now approved to treat discoid lupus, systemic lupus erythematosus, and rheumatoid arthritis.

  • Pharmacotherapy for obesity: What you need to know
    Sophie Bersoux, MD, MPH, Tina H. Byun, MD, Swarna S. Chaliki, MD and Kenneth G. Poole, MD, MBA
    Cleveland Clinic Journal of Medicine December 2017, 84 (12) 951-958; DOI: https://doi.org/10.3949/ccjm.84a.16094

    Weight-loss drugs are not magic pills, but they can help when used along with diet, exercise, and other lifestyle changes.

  • Dual antiplatelet therapy for acute coronary syndromes: How long to continue?
    Dual antiplatelet therapy for acute coronary syndromes: How long to continue?
    Meghana Halkar, MD and A. Michael Lincoff, MD
    Cleveland Clinic Journal of Medicine September 2016, 83 (9) 675-688; DOI: https://doi.org/10.3949/ccjm.83a.15092

    After drug-eluting stent placement, at least 12 months of dual antiplatelet therapy is recommended. Would longer be better?

  • Ceftaroline fosamil: A super-cephalosporin?
    Riane J. Ghamrawi, PharmD, BCPS, Elizabeth Neuner, PharmD and Susan J. Rehm, MD
    Cleveland Clinic Journal of Medicine July 2015, 82 (7) 437-444; DOI: https://doi.org/10.3949/ccjm.82a.14105

    Ceftaroline fosamil is the first beta-lactam with clinically useful activity against methicillin-resistant Staphylococcus aureus.

  • Denosumab: A novel antiresorptive drug for osteoporosis
    Ernest Suresh, MD, FRCP and Bo Abrahamsen, MD, PhD
    Cleveland Clinic Journal of Medicine February 2015, 82 (2) 105-114; DOI: https://doi.org/10.3949/ccjm.82a.13173

    What denosumab is, how it works, how well it works, and practical prescribing tips.

  • Hepatitis C virus: Here comes all-oral treatment
    Hepatitis C virus: Here comes all-oral treatment
    Mohannad Dugum, MD and Robert O’shea, MD
    Cleveland Clinic Journal of Medicine March 2014, 81 (3) 159-172; DOI: https://doi.org/10.3949/ccjm.81a.13155

    Direct-acting antiviral drugs open the door for an all-oral regimen, potentially eliminating the need for interferon and thus avoiding its harsh side effects.

  • Canagliflozin: Improving diabetes by making urine sweet
    Mary Vouyiouklis, MD
    Cleveland Clinic Journal of Medicine November 2013, 80 (11) 683-687; DOI: https://doi.org/10.3949/ccjm.80a.13053

    Canagliflozin is the first of a new class of diabetes drugs that lower glucose by increasing its urinary excretion. An overview of its mechanism, uses, risks, and benefits.

Pages